Coloplast Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 3/6
Coloplast verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 4.9%, während die Gewinne der Branche Medical Equipment jährlich um gewachsen und zwar um 9.7%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 8.9%. Die Eigenkapitalrendite von Coloplast beträgt 28.2% und die Nettomargen betragen 18.7%.
Wichtige Informationen
4.9%
Wachstumsrate der Gewinne
4.0%
EPS-Wachstumsrate
| Medical Equipment Wachstum der Industrie | -1.7% |
| Wachstumsrate der Einnahmen | 8.9% |
| Eigenkapitalrendite | 28.2% |
| Netto-Marge | 18.7% |
| Nächste Ertragsaktualisierung | 04 Feb 2025 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's
Nov 13
Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Nov 08Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly
Oct 18Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 23Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?
Aug 22Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price
Jul 17These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well
Jun 29Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations
May 21Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00
May 10Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report
May 09A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)
Apr 26There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price
Apr 08Is Coloplast (CPH:COLO B) A Risky Investment?
Mar 21Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)
Jan 09Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings
Dec 22These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well
Dec 04Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues
Nov 16A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)
Sep 30Is Coloplast (CPH:COLO B) A Risky Investment?
Jun 28Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price
Jun 10Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly
Mar 22Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price
Mar 01These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well
Dec 14Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's
Nov 26Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being
Nov 25Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year
Nov 11With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case
Oct 25Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)
Aug 26These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well
Jul 27Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching
Jul 12Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?
May 23Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00
May 08Aufschlüsselung der Einnahmen und Ausgaben
Wie Coloplast Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 27,030 | 5,052 | 10,069 | 913 |
| 30 Jun 24 | 26,303 | 4,967 | 9,675 | 925 |
| 31 Mar 24 | 25,526 | 4,965 | 9,252 | 901 |
| 31 Dec 23 | 25,001 | 4,868 | 8,934 | 889 |
| 30 Sep 23 | 24,500 | 4,783 | 8,632 | 872 |
| 30 Jun 23 | 24,333 | 4,784 | 8,581 | 858 |
| 31 Mar 23 | 24,074 | 4,801 | 8,550 | 864 |
| 31 Dec 22 | 23,515 | 4,626 | 8,272 | 877 |
| 30 Sep 22 | 22,579 | 4,706 | 7,800 | 866 |
| 30 Jun 22 | 21,620 | 4,781 | 7,336 | 856 |
| 31 Mar 22 | 20,606 | 4,746 | 6,828 | 819 |
| 31 Dec 21 | 19,857 | 4,896 | 6,446 | 774 |
| 30 Sep 21 | 19,426 | 4,825 | 6,249 | 755 |
| 30 Jun 21 | 18,916 | 4,561 | 6,098 | 723 |
| 31 Mar 21 | 18,500 | 4,304 | 5,938 | 720 |
| 31 Dec 20 | 18,570 | 4,241 | 5,993 | 725 |
| 30 Sep 20 | 18,544 | 4,197 | 6,086 | 708 |
| 30 Jun 20 | 18,572 | 3,949 | 6,113 | 698 |
| 31 Mar 20 | 18,752 | 4,020 | 6,199 | 691 |
| 31 Dec 19 | 18,330 | 3,974 | 6,118 | 680 |
| 30 Sep 19 | 17,939 | 3,873 | 5,970 | 692 |
| 30 Jun 19 | 17,555 | 4,119 | 5,753 | 686 |
| 31 Mar 19 | 17,181 | 3,999 | 5,626 | 671 |
| 31 Dec 18 | 16,815 | 3,896 | 5,488 | 663 |
| 30 Sep 18 | 16,449 | 3,845 | 5,375 | 640 |
| 30 Jun 18 | 16,195 | 3,816 | 5,315 | 619 |
| 31 Mar 18 | 15,882 | 3,778 | 5,211 | 605 |
| 31 Dec 17 | 15,728 | 3,791 | 5,104 | 594 |
| 30 Sep 17 | 15,528 | 3,797 | 4,994 | 574 |
| 30 Jun 17 | 15,287 | 3,211 | 4,880 | 565 |
| 31 Mar 17 | 15,061 | 3,279 | 4,785 | 551 |
| 31 Dec 16 | 14,780 | 3,264 | 4,731 | 521 |
| 30 Sep 16 | 14,681 | 3,143 | 4,693 | 509 |
| 30 Jun 16 | 14,563 | 1,297 | 4,690 | 494 |
| 31 Mar 16 | 14,417 | 1,028 | 4,627 | 477 |
| 31 Dec 15 | 14,264 | 927 | 4,583 | 458 |
| 30 Sep 15 | 13,909 | 899 | 4,488 | 442 |
| 30 Jun 15 | 13,502 | 3,162 | 4,343 | 437 |
| 31 Mar 15 | 13,096 | 3,241 | 4,220 | 418 |
| 31 Dec 14 | 12,666 | 2,407 | 4,088 | 406 |
| 30 Sep 14 | 12,428 | 2,390 | 4,002 | 390 |
| 30 Jun 14 | 12,184 | 2,298 | 3,959 | 375 |
| 31 Mar 14 | 12,008 | 2,220 | 3,944 | 370 |
| 31 Dec 13 | 11,833 | 2,874 | 3,889 | 382 |
Qualität der Erträge: COLO B hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: COLO BDie aktuellen Gewinnspannen (18.7%) sind niedriger als im letzten Jahr (19.5%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: COLO BIn den letzten 5 Jahren sind die Gewinne von 4.9% jährlich gestiegen.
Beschleunigtes Wachstum: COLO BDas Gewinnwachstum des Unternehmens im letzten Jahr (5.6%) übertrifft seinen 5-Jahres-Durchschnitt (4.9% pro Jahr).
Erträge im Vergleich zur Industrie: COLO B Das Gewinnwachstum im vergangenen Jahr (5.6%) übertraf nicht die Entwicklung der Branche Medical Equipment 13% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: Die Eigenkapitalrendite (28.16%) von COLO B ist zwar hoch, aber aufgrund der hohen Verschuldung des Unternehmens ist diese Kennzahl verzerrt.